C. Blanckmeister

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Y. Bang, E. Van Cutsem, E. Raymond, 2011, The New England journal of medicine.

Macrophage Activation by Cross‐Linked Dextran

C. Blanckmeister, D. H. Sussdorf, Carolyn A. Blanckmeister, 1985, Journal of leukocyte biology.

6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial

E. Raymond, A. Vinik, P. Metrakos, 2009 .

Antigen-specific, I-A-restricted suppressor hybridomas with spontaneous cytolytic activity. Functional properties and lack of rearrangement of the T cell receptor beta chain genes

M. Davis, G. Hämmerling, K. Yamamoto, 1985, The Journal of experimental medicine.

Phase III, Randomized, Double-blind Trial of Sunitinib Versus Placebo in Patients With Progressive, Well-differentiated Pancreatic Islet Cell Tumours

Y. Bang, E. Raymond, A. Vinik, 2009 .

Multicenter international work flow study of an automated polymerase chain reaction instrument.

P E Klapper, D L Jungkind, T Fenner, 1998, Clinical chemistry.